Principal Financial Group Inc. Has $328,000 Stake in MiMedx Group, Inc. (NASDAQ:MDXG)

Principal Financial Group Inc. raised its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 55,495 shares of the company’s stock after buying an additional 3,292 shares during the period. Principal Financial Group Inc.’s holdings in MiMedx Group were worth $328,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of MDXG. Isthmus Partners LLC increased its holdings in shares of MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after buying an additional 91,714 shares in the last quarter. Blue Trust Inc. acquired a new stake in shares of MiMedx Group during the third quarter worth approximately $30,000. Point72 Asset Management L.P. acquired a new stake in shares of MiMedx Group during the second quarter worth approximately $40,000. Quest Partners LLC acquired a new stake in shares of MiMedx Group during the second quarter worth approximately $81,000. Finally, Nemes Rush Group LLC increased its holdings in shares of MiMedx Group by 93.6% during the second quarter. Nemes Rush Group LLC now owns 16,224 shares of the company’s stock worth $112,000 after buying an additional 7,844 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Stock Performance

Shares of MiMedx Group stock opened at $9.20 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The firm has a market cap of $1.35 billion, a P/E ratio of 16.73 and a beta of 1.94. The firm has a 50 day simple moving average of $6.60 and a 200 day simple moving average of $6.84. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $9.49.

Analysts Set New Price Targets

Several research firms have recently weighed in on MDXG. Craig Hallum dropped their price objective on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st. StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price target on shares of MiMedx Group in a report on Thursday, August 1st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, MiMedx Group presently has an average rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.